Replimune Group (NASDAQ:REPL) Trading Down 5.2% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price traded down 5.2% on Monday . The company traded as low as $8.70 and last traded at $8.98. 921,331 shares traded hands during trading, a decline of 81% from the average session volume of 4,867,033 shares. The stock had previously closed at $9.47.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Jefferies Financial Group reissued a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a report on Friday, May 29th. Finally, Leerink Partners reissued a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Seven equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $4.88.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The stock’s fifty day moving average is $5.11 and its two-hundred day moving average is $7.27. The firm has a market cap of $726.23 million, a price-to-earnings ratio of -2.56 and a beta of 0.91.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

Large investors have recently modified their holdings of the company. Fcpm Iii Services B.V. increased its stake in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after buying an additional 248,672 shares during the period. Erste Asset Management GmbH increased its stake in Replimune Group by 13,597.5% during the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after buying an additional 1,618,100 shares during the period. Braidwell LP increased its stake in Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after buying an additional 2,327,205 shares during the period. Readystate Asset Management LP increased its stake in Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after buying an additional 2,433,292 shares during the period. Finally, Quinn Opportunity Partners LLC acquired a new position in Replimune Group during the 3rd quarter valued at about $2,727,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.